The pharmacokinetics and pharmacodynamics pathway of sunitinib, a multikinase inhibitor used in the treatment of cancer, in particular for advanced renal cell carcinoma. The drug binds to the intracytoplasmic domain of tyrosine kinase receptors blocking the downstream signaling cascade. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.